The skeletal system is the most common site of metastatic cancer spread. Bone metastases are often associated with severe morbidity, pain and functional impairment. Timely diagnosis and proper treatment may decrease morbidity, improve quality of life and in some cases even improve survival. External beam radiotherapy may effectively give pain relief in patients with painful bone metastases. In bone metastases from castration-resistant prostate cancer or urothelial bladder cancer, treatment with zoledronic acid or denosumab may reduce skeletal-related events. In contrast to castration-resistant prostate cancer, in patients with bone metastases from bladder cancer such treatment may even improve survival. On the other hand, the efficacy of these agents is questionable in patients with bone involvement from metastatic renal cell carcinoma or germ cell tumors. When bisphosphonates or denosumab are considered in such cases, the potential benefits of treatment should be critically weighed against the risk of side effects. In germ cell tumors, bone metastases may be cured by cisplatin-based chemotherapy, however, there are only limited data on the specific management of residual disease. Oligometastases may be treated by stereotactic radiotherapy or - especially in patients with renal cell carcinoma - by surgical resection and endoprosthetic replacement. Limited data are available on the management of bone involvement in germ cell tumors. Decisions on the resection or local radiotherapy of residual disease should be individualized considering the overall response and the feasibility and risks of resection.

Keywords:
Bone metastases, Radiotherapy, Stereotactic, Denosumab, Zoledronic acid, Urologic neoplasms
1.
Poon M, Zeng L, Zhang L, Lam H, Emmenegger U, Wong E, Bedard G, Lao N, Chow R, Chow E: Incidence of skeletal-related events over time from solid tumour bone metastases reported in randomised trials using bone-modifying agents. Clin Oncol (R Coll Radiol) 2013;25:435-444.
2.
Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K: New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 2013;63:309-320.
3.
Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C: Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379:39-46.
4.
Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, Howell D, Konski A, Kachnic L, Lo S, Sahgal A, Silverman L, von Gunten C, Mendel E, Vassil A, Bruner DW, Hartsell W; American Society for Radiation Oncology (ASTRO): Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011;79:965-976.
5.
Chow E, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, Brundage MD, Nabid A, Tissing-Tan CJ, Oei B, Babington S, Demas WF, Wilson CF, Meyer RM, Chen BE, Wong RK: Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol 2014;15:164-171.
6.
Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, van As NJ: Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013;14:e28-e37.
7.
Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders PFA, Powles T, Staehler M, Volpe A: Guidelines on renal cell carcinoma. Update 2014. http://www.uroweb.org/gls/pdf/10%20Renal%20Cell%20Carcinoma_LR.pdf (visited May 1, 2014).
8.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla N, Joniau S, Mason MD, Matveev V, Mottet N, van der Kwast TH, Wiegel T, Zattoni F: EAU guidelines on prostate cancer. Update 2014. http://www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf (visited May 1, 2014).
9.
Deutsche Gesellschaft für Urologie e. V.: Konsultationsfassung 2014. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. AWMF-Register-Nummer (034/022OL) Version 2.2 - 2. Aktualisierung 2014. http://www.dgu.de/fileadmin/MDB/PDF/konsultationsfassung-leitlinie-prostatakarzinom.pdf (visited May 1, 2014).
10.
National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline®): Prostate Cancer, Version 2.2014. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (visited May 1, 2014).
11.
National Institute for Health and Care Excellence (NICE): NICE clinical guideline 58: Prostate cancer. Diagnosis and treatment. http://www.nice.org.uk/nicemedia/live/11924/39687/39687.pdf (visited May 1, 2014).
12.
American Urological Association: Guideline for the management of clinically localized prostate cancer: 2007 update (reviewed and validity confirmed 2011). http://www.auanet.org/common/pdf/education/clinical-guidance/Prostate-Cancer.pdf (visited July 30, 2014).
13.
Tabata K, Niibe Y, Satoh T, Tsumura H, Ikeda M, Minamida S, Fujita T, Ishii D, Iwamura M, Hayakawa K, Baba S: Radiotherapy for oligometastases and oligo-recurrence of bone in prostate cancer. Pulm Med 2012;2012:541656.
14.
Cathomas R, Bajory Z, Bouzid M, El Ghoneimy A, Gillessen S, Goncalves F, Kacso G, Kramer G, Milecki P, Pacik D, Tantawy W, Lesniewski-Kmak K: Management of bone metastases in patients with castration-resistant prostate cancer. Urol Int 2014;92:377-386.
15.
Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, Decaestecker K, Villeirs G, Vuye P, Ost P: Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 2013;11:27-32.
16.
Bhattasali O, Chen LN, Tong M, Lei S, Collins BT, Krishnan P, Kalhorn C, Lynch JH, Suy S, Dritschilo A, Dawson NA, Collins SP: Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer. Front Oncol 2013;3:293.
17.
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B; Zoledronic Acid Prostate Cancer Study Group: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
18.
Saad F: Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 2002;1:145-152.
19.
Saad F, Chen YM, Gleason DM, Chin J: Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 2007;5:390-396.
20.
Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-822.
21.
Arzneimittelkommission der deutschen Ärzteschaft: Sicherheitsaspekte bei der Anwendung von Denosumab (Prolia®, Xgeva®): Fälle von Vaskulitis und Risiko für schwere Hypokalzämien. Dtsch Arztebl 2014;111:472-473.
22.
Schmitz-Dräger BJ, Weiss C, Ebert T, Dörsam J, Bismarck E: Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration. Urol Int 2013;90:329-333.
23.
Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C: Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013;31:3800-3806.
24.
Wirth M, Tammela T, Cicalese V, Gomez Veiga F, Delaere K, Miller K, Tubaro A, Schulze M, Debruyne F, Huland H, Patel A, Lecouvet F, Caris C, Witjes W: Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol 2014, Epub ahead of print.
25.
Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR: Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009;10:872-876.
26.
European Medicines Agency (EMA): Questions and answers on the outcome of an application for Xgeva to be used in patients with castration-resistant prostate cancer at high risk of spreading to the bones. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/002173/WC500153128.pdf (visited May 1, 2014).
27.
Food and Drug Administration (FDA): FDA ODAC Briefing Document. February 8, 2012. BLA 125320/28: Denosumab (Xgeva™), Amgen Inc. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM290400.pdf (visited May 1, 2014).
28.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-223.
29.
Fuchs B, Trousdale RT, Rock MG: Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment. Clin Orthop Relat Res 2005;431:187-192.
30.
Hwang N, Nandra R, Grimer RJ, Carter SR, Tillman RM, Abudu A, Jeys LM: Massive endoprosthetic replacement for bone metastases resulting from renal cell carcinoma: factors influencing patient survival. Eur J Surg Oncol 2014;40:429-434.
31.
Saad F, Eastham JA: Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Semin Oncol 2010;37(suppl 1):S38-S44.
32.
McKay RR, Lin X, Perkins JJ, Heng DY, Simantov R, Choueiri TK: Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol 2014, Epub ahead of print.
33.
Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebrét T, Ribal MJ, Sherif A, van der Heijden AG: Guidelines on muscle-invasive and metastatic bladder cancer. Update 2014. http://www.uroweb.org/gls/pdf/07%20Muscle%20Invasive%20BC_LR.pdf (visited May 1, 2014).
34.
Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M: A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 2010;15:382-389.
35.
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, Nicolai N, Oldenburg J: Guidelines on testicular cancer. Update 2011. http://www.uroweb.org/gls/pdf/11%20Testicular%20Cancer_LR.pdf (visited May 1, 2014).
36.
Jamal-Hanjani M, Karpathakis A, Kwan A, Mazhar D, Ansell W, Shamash J, Harper P, Rudman S, Powles T, Chowdhury S: Bone metastases in germ cell tumours: lessons learnt from a large retrospective study. BJU Int 2013;112:176-181.
37.
Oechsle K, Bokemeyer C, Kollmannsberger C, Mayer F, Berger LA, Oing C, Honecker F: Bone metastases in germ cell tumor patients. J Cancer Res Clin Oncol 2012;138:947-952.
38.
Froehner M, Aikele P, Beuthien-Baumann B, Kittner T, Oehlschlaeger S, Wirth MP: Magnetic resonance imaging of bone metastases in patients with nonseminomatous germ cell tumors. Urol Oncol 2007;25:201-206.
39.
Hakenberg OW, Compérat E, Minhas S, Necchi A, Protzel C, Watkin N: Guidelines on penile cancer. http://www.uroweb.org/gls/pdf/12%20Penile%20Cancer_LR.pdf (visited May 1, 2014).
40.
National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline®): Penile Cancer, Version 1.2014. http://www.nccn.org/professionals/physician_gls/pdf/penile.pdf (visited May 1, 2014).
41.
Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B: Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19:420-432.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.